Illumina, Inc. (NASDAQ: ILMN) today introduced the world's largest genome-wide genetic perturbation dataset, being built to ...
The BLA was resubmitted in 2025, after Atara and the FDA aligned on the criteria and addressed the initial CRL conditions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback